Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Q3 2024 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen, and welcome, everyone, to the Maravai LifeSciences Third Quarter 2024 Earnings Conference Call.
Maravai Lifesciences Holdings Inc. (MRVI)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | 12 West Capital Management Joel Ramin | 14,011,179 | $116,432,897 | +7% | 11.91% |
| 2. | Braidwell LP Alex Karnal | 8,353,287 | $69,415,815 | -8% | 1.96% |
| 3. | Millennium Management Israel Englander | 4,325,312 | $35,943,343 | -28% | 0.01% |
| 4. | Renaissance Technologies Jim Simons | 4,138,475 | $34,390,727 | +7% | 0.05% |
| 5. | Alyeska Investment Group Anand Parekh | 2,168,348 | $18,018,972 | +1% | 0.09% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.75 | 17,500 | Director | 70,046 | 2024-11-12 | Filing | |
| $5.64 | 175,000 | Officer, Director | 175,000 | 2024-11-11 | Filing | |
| $26.94 | 35,000 | Officer, Director | 35,000 | 2020-11-25 | Filing | |
| $27.00 | 20,000 | Director | 31,852 | 2020-11-24 | Filing | |
| $27.00 | 18,888 | Officer | 18,888 | 2020-11-24 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $9.82 | 9,940,974 | 20,150,005 | 2024-05-28 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 21,681,033 | $142,010,766 | 8.61% | |
| 2. | 10,003,894 | $65,525,506 | 0% | |
| 3. | 6,481,668 | $42,454,926 | 0% | |
| 4. | 6,014,575 | $39,395,465 | 0.01% | |
| 5. | 5,169,176 | $33,858,103 | 0.05% |
News See All
10 Best Biotech Stocks To Buy Under $20
The biotechnology industry is experiencing rapid growth, driven by increasing demand for innovative treatments, technological advancements, and government support.
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Q2 2024 Earnings Call Transcript
Operator: Thank you for standing by and welcome to the Maravai LifeSciences Second Quarter 2024 Earnings Conference Call. All lines have been placed on mute to prevent any background noise.
Here’s Why RGAIA Considers Maravai LifeSciences Holdings' (MRVI) Margin Structure as the Best
RGA Investment Advisors, an investment management company released its first quarter 2024 investor letter. A copy of the letter can be downloaded here.
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Q1 2024 Earnings Call Transcript
Operator: Good day, ladies and gentlemen. And welcome to the First Quarter 2024 Maravai LifeSciences Earnings Conference Call. As a reminder, this call is being recorded.
Should You Sell Maravai LifeSciences (MRVI)?
ClearBridge Investments, an investment management firm, released its fourth-quarter 2023 “Mid Cap Strategy” investor letter, which can be downloaded here.
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Q4 2023 Earnings Call Transcript
Operator: Good afternoon and thank you for standing by. At this time, we would like to welcome everyone to the Q4 2023 Maravai LifeSciences Earnings Conference Call.
Will Maravai LifeSciences Holdings (MRVI) Pipeline Start to Bear Fruit?
Baron Funds, an investment management company, released its “Baron Discovery Fund” fourth quarter 2023 investor letter. A copy of the same can be downloaded here.
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Q3 2023 Earnings Call Transcript
Operator: Ladies and gentlemen, thank you for standing by. My name is Tammy and I will be your conference operator today.
12 Cheap Biotech Stocks Smart Investors Are Piling Into
In this piece, we will take a look at 12 cheap biotechnology stocks that smart investors are piling into.
Billionaire Hedge Funds
